Key facts
- ReSpindle’s last known valuation is $2.8M (Oct 2025).
- Notable investors include ZAS Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for ReSpindle
- ·The full record, as it builds
Funding rounds
No funding rounds for ReSpindle are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ReSpindle
Developer of an AI reproductive medicine computer vision platform designed to advance reproductive medicine by improving embryo selection accuracy and enhancing IVF success rates. The company offers a revolutionary AI technology that analyzes oocyte spindle morphology to predict embryo ploidy, enabling customers to enhance IVF success rates, improve embryo selection accuracy and reduce the need for invasive genetic testing.
- Sector
- Healthcare
- HQ
- Maastricht, Netherlands
- Founded
- 2024
- Website
- respindle.com/
- Ownership
- Privately Held (backing)
ReSpindle doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ReSpindle shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ReSpindle in its N-PORT filings yet. We sweep new filings monthly.